Gilead has inked a deal to license Leo Pharma's portfolio of oral STAT6 candidates for inflammatory diseases, less than a month after Johnson & Johnson …
Ayisha Sharma is a Biopharma Breaking News Reporter at Endpoints News. She specializes in a diverse range of topics within medicine and healthcare, including biotech, healthcare technology, and the intersection of finance and personal finance in the biopharma sector. Ayisha's work has also been featured in Citeline and NewsBreak, highlighting her expertise in emerging trends such as cannabis and psychedelics, as well as the startup landscape in venture capital.